Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
D1 Capital Partners
BioCentury | Nov 3, 2023
Finance
Lexeo cuts IPO price, becomes latest to lose value in first session
With gene therapy company’s dip Friday, seven of 10 major 2023 NASDAQ biotech listings have now traded down in the aftermarket since pricing
BioCentury | Mar 30, 2022
Emerging Company Profile
SalioGen: genome editing without viruses or nucleases
The Cambridge, Mass.-based biotech is using mammalian enzymes to insert DNA into the genome without causing breaks
BioCentury | Jan 6, 2022
Finance
Jan. 5 Quick Takes: Eventide leads mega-round by Korro
Plus Saliogen raises $115M series B and updates from
BioCentury | Sep 10, 2021
Product Development
Sept. 9 Quick Takes: Obsidian readies for IPO with $115M crossover round
Plus: Venture rounds for Lexeo, Evommune, Alamar, and setbacks for Humanigen, Sanofi and more
BioCentury | May 18, 2021
Finance
May 18 Quick Takes: Temasek backs Wilson, Yamada to form G2 Bio; plus PathAI, Interius, Vedere II and more
Singapore-based Temasek will supply $200 million to G2 Management Co. Inc. to foster the development of therapies from the University of Pennsylvania's Gene Therapy Program, led by James Wilson.
BioCentury | Apr 8, 2021
Finance
Venture rounds for Icosavax, Nucleix, Vizgen, Inscripta, Metagenomi and Volastra
Vaccine developer Icosavax Inc. raised $100 million in a series B round led by RA Capital Management. New investors Janus Henderson Investors, Perceptive Advisors, Viking Global Investors, Cormorant
BioCentury | Mar 17, 2021
Deals
March 17 Quick Takes: Merck-Amathus enter neurodegenerative disease collaboration; plus WuXi, Sana-Fujifilm, Rubius, Inflammatix, StrideBio and more
Amathus Therapeutics entered a strategic collaboration with Merck & Co. Inc. (NYSE:MRK) to develop small molecules for neurodegenerative diseases. Under the deal, Amathus will identify and conduct
Items per page:
1 - 7 of 7